Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.52 |
| ▸ | ATR | Q13535 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL175243 | 0.83 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20212531 | 0.80 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL470233 | 0.79 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL15051784 | 0.73 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL470240 | 0.71 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGHPGDS | |
| SCHEMBL17255824 | 0.70 | PIK3CD (0.88) | PIK3CDPIK3CAPIK3CBPIK3CGHPGDS | |
| SCHEMBL470203 | 0.70 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGATR | |
| Hydrochloric Acid SCHEMBL17255819 | 0.70 | PIK3CD (0.87) | PIK3CDPIK3CAPIK3CBPIK3CGHPGDS | |
| SCHEMBL23140774 | 0.70 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| Nemiralisib SCHEMBL18281137 | 0.69 | PIK3CD (0.97) | PIK3CDPIK3CAPIK3CBPIK3CGHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10383879-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190175608-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20180325911-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2018-11-15 | — | — | US | disclosed |
| EP-3260453-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2017-12-27 | — | — | EP | disclosed |
| EP-2899191-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-8580797-B2 | Compounds | Glaxo Smith Kline Intellectual Property Development Limited (GB) | 2013-11-12 | — | — | US | disclosed |
| US-8575162-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-20130131080-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130096117-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-04-18 | — | — | US | disclosed |
| US-20130029985-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2424864-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029985-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20130131080-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-10383879-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20190328744-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | PIK3CD 73/4885PIK3CA 70/4885PIK3CB 51/4885 |
| US-20180325911-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
| US-20190175608-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20130096117-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.